FilingReader Intelligence
BrightGene raises 500m yuan, reports mixed results
August 11, 2025 at 08:32 AM UTC•By FilingReader AI
BrightGene Bio-Medical Technology's 500 million yuan private share issuance to its controlling shareholder was approved by the Shanghai Stock Exchange, with proceeds earmarked for working capital and loan repayment.
The company reported 2024 net profit of 141.3 million yuan, down from 173.4 million yuan previously, while making significant capital investments in production facilities.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Supplementary Source Documents
Prospectus for the private placement of shares (draft submission)August 11, 2025 at 08:00 AM UTC
Announcement regarding the acceptance by the Shanghai Stock Exchange of the application for the 2024 non-public offering of A shares to specific objects.August 11, 2025 at 08:00 AM UTC
Sponsor recommendation letter from Minsheng Securities Company Limited regarding the public issuance of shares to specific investors by Borui Biology Pharmaceutical (Suzhou) Company LimitedAugust 11, 2025 at 08:00 AM UTC
Sponsor recommendation letter from Minsheng Securities Company Limited regarding the issuance of shares to specific objects by Bory Biopharmaceutical (Suzhou) Co., Ltd.August 11, 2025 at 08:00 AM UTC
Legal opinion of Jingtian & Gongcheng Attorneys at Law, Beijing, on the 2024 non-public issuance of A shares by Borui Biopharmaceutical (Suzhou) Co., Ltd. to specific investorsAugust 11, 2025 at 08:00 AM UTC
SSE:688166•Shanghai Stock Exchange
News Alerts
Get instant email alerts when BrightGene Bio-Medical Technology publishes news
Free account required • Unsubscribe anytime